Ads
related to: lipitor price philippines
Search results
Results From The WOW.Com Content Network
From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years. [ 117 ] and $13 billion a year at its peak, [ 118 ] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania.The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
Jb Reed, Bloomberg via Getty Images By Emily Jane Fox CVS (CVS) charges $150 for a monthly prescription of the generic version of the cholesterol drug Lipitor. The same drug goes for $17 at Costco.
Rank Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469
Amlodipine/atorvastatin, sold under the brand name Caduet among others, is a fixed-dose combination medication for the treatment of high cholesterol and high blood pressure. It contains a statin and a calcium channel blocker .
Cholesterol synthesis appears to occur mostly at night, [139] so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, [140] [141] but have shown no difference in the long-acting ...
On 9 November 2012, Ranbaxy halted production and recalled 41 lots of atorvastatin due to glass particles being found in some bottles. [ 21 ] [ 22 ] Also in 2012, an apparent dosage mistake was reported in which 20 mg tablets were found in a bottle of atorvastatin labeled as containing 10 mg tablets; this led in 2014 to the voluntary recall in ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]